Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb is projected to generate nearly $860mn in adjusted earnings before interest, taxation, depreciation and ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb is one of the leading contact-lens suppliers in the world. Bausch Health and Goldman Sachs declined to comment to the FT. Bausch + Lomb is headed by Brent Saunders, a longtime ...